A Potential Turning Point for Celiac Disease: Teva’s TEV-408 Shows Promise in Phase 2a Trials
By Medical Science Correspondent For millions of individuals living with celiac disease, the current standard of care—a strict, lifelong gluten-free diet—is a demanding and often insufficient solution. Beyond the logistical…







